Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Arcellx Inc, a biotechnology firm focused on cell therapy innovations, has announced impressive results from its studies on ...

AQUILA (NCT03301220) is a randomized, multicenter phase 3 study investigating Darzalex Faspro versus active monitoring in patients (n=390) with high-risk smoldering multiple myeloma. The primary ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...